Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Financial calendar
Corporate governance
Corporate governance statements
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
ESG
Email alerts
Newsroom
Press Releases
Image library
Glossary
Email alerts
Careers
Search
Research and development
Scientific papers and presentations
Sharing our discoveries and developments in our tireless pursuit of breakthrough therapies
Newest first
Oldest first
Posters & Papers
Presentations
Search
Reset
11/06/2024
Nature Conferences: Cancer Immunotherapy – June 2024 | Targeted Delivery of Neoantigens to APCs using Vaccibodies Encoded in mRNA Results in Stronger and Broader T Cell Responses, and Improved Tumor Control
01/05/2024
7th International Neoantigen Summit – May 2024 | Optimizing RNA/DNA-Based Vaccine Design by Identifying Key Characteristics to Ensure Success of the Therapy
16/04/2024
AACR San Diego – 2024 | Targeting of neoantigen cancer vaccines to antigen presenting cells results in faster and broader T cell responses whether encoded in DNA or mRNA
19/03/2024
ASIT Boston – 2024 | A Tolerizing APC-Targeted Vaccibody Vaccine Ameliorates Disease in Mouse Models of Experimental Autoimmune Encephalomyelitis and Non-Obese Diabetes
31/10/2023
SITC – 2023 | Predictive value of circulating tumor DNA in patients with advanced HPV16-positive cervical cancer treated with VB10.16 in combination with atezolizumab
Pages:
1
2
3
4
5
6
7
8
9
10
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
